Skip to main content
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. — Investor Relations & Filings

Ticker · NAGE ISIN · US1710774076 LEI · 529900OPI7B8JPXCVS70 US Manufacturing
Open in API
Filings indexed 954 across all filing types
Latest filing 2010-01-21 Capital/Financing Update
Country US United States of America
Listing US NAGE

About Niagen Bioscience, Inc.

https://www.niagenbioscience.com/

Niagen Bioscience, Inc. (formerly ChromaDex) is a bioscience company focused on the science of nicotinamide adenine dinucleotide (NAD+). The company aims to improve healthspan and support healthy aging by developing products that restore and optimize cellular NAD+ levels. Its core proprietary ingredient is Niagen®, a patented and clinically studied form of nicotinamide riboside (NR), a precursor to NAD+. Niagen® is the key component in the company's consumer dietary supplement brand, Tru Niagen®, and is also developed for the food, beverage, and pharmaceutical markets. The company's research is supported by numerous human clinical studies, a portfolio of over 50 owned and licensed patents, and collaborations with global research institutions.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2010
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a subscription agreement and the status of payments related to a financing transaction, specifically the failure to receive payment for shares under a subscription agreement. This is an update on a financing activity rather than a full financial report or earnings release. The document length is 3960 characters, which is relatively short and focused on a specific event. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2010-01-21 English
Capital/Financing Update 2009
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a subscription agreement and related financing details, including share purchases and warrants, but does not contain comprehensive financial statements or quarterly/yearly results. The document length is 3248 characters, which is relatively short and focused on a specific financing event. Therefore, this filing is best classified as a Capital/Financing Update (CAP).
2009-12-31 English
SUBSCRIPTION AGREEMENT
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a private placement equity financing transaction where the company raised capital by selling shares and warrants. It includes details about the subscription agreement, share sales, and registration rights. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a proxy, earnings release, or management discussion. It is clearly an update on capital raising activity and changes in the company's capital structure. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2009-12-03 English
FORM 10-Q FOR PERIOD ENDED OCTOBER 3, 2009
Interim / Quarterly Report Q3 2009
2009-11-17 English
FORM 10-Q
Interim / Quarterly Report Q2 2009
2009-08-18 English
FORM 10-Q
Interim / Quarterly Report Q1 2009
2009-05-15 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.